(Q53461837)

14 May 2018

title

Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. (English)

1 reference

14 May 2018

1 reference

1 reference

Chiaki Tanaka

1

1 reference

14 May 2018

Ophelia Q P Yin

2

1 reference

14 May 2018

Tom Smith

3

1 reference

14 May 2018

Venkat Sethuraman

4

1 reference

14 May 2018

Karen Grouss

5

1 reference

14 May 2018

Lawrence Galitz

6

1 reference

14 May 2018

Robert Harrell

7

1 reference

14 May 2018

Horst Schran

8

1 reference

14 May 2018

publication date

11 August 2010

1 reference

14 May 2018

The Journal of Clinical Pharmacology

published in

1 reference

14 May 2018

volume

51

1 reference

14 May 2018

issue

1

1 reference

14 May 2018

page(s)

75-83

1 reference

14 May 2018

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270010367428

AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010367428

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010367428

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010367428

Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010367428

Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010367428

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010367428

Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010367428

Cytochrome p450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010367428

Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010367428

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010367428

Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010367428

Pharmacokinetic interactions with rifampicin : clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010367428

Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010367428

The Conduct of In Vitro and In Vivo Drug-Drug Interaction Studies: A PhRMA Perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010367428

Interindividual and intraindividual variability of the urinary 6beta-Hydroxycortisol/Cortisol ratio in Chinese subjects: implications of its use for evaluating CYP3A activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010367428

Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010367428

Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010367428

Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010367428

Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010367428

Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010367428

Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010367428

21 January 2018

Identifiers

DOI

10.1177/0091270010367428

1 reference

14 May 2018

1 reference

14 May 2018